Drug intelligence / Profile preview

covalent CBLB inhibitor

Development stage: Preclinical
Lead developer: BridGene Biosciences
Modality: Small Molecules
Administration: Oral

Overview

BridGene Biosciences is developing a covalent small molecule inhibitor of CBLB (Casitas B-lineage lymphoma proto-oncogene B) for the treatment of solid tumors. CBLB is an E3 ubiquitin ligase that functions as a critical negative regulator of T-cell and NK-cell activation; its inhibition is a strategy in cancer immunotherapy to promote an anti-tumor immune response. The candidate was identified using BridGene's IMTAC™ (Isobaric Mass Tagged Affinity Characterization) chemoproteomic platform, which screens covalent small molecules against the whole proteome in live cells. As of the latest reports, the program is in the lead optimization phase of preclinical development.

Other names: CBLB inhibitorcovalent CBL-B inhibitor

Targets

CBLB (CBL-B)

Beyond the preview

Go deeper on covalent CBLB inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on covalent CBLB inhibitor.

Explore the full profile